Codexis, Inc. is a technology solutions provider that develops and commercializes high-performance enzymes and protein-based tools to improve therapeutics manufacturing. The company operates through two primary business segments: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform utilizes enzymatic tools and processes to enable the large-scale manufacture of RNA interference (RNAi) therapeutics, specifically small interfering ribonucleic acid (siRNA), offering an alternative to traditional solid-phase oligonucleotide synthesis. This segment includes the ECO Synthesis Innovation Lab, which provides process development and non-GMP-grade siRNA synthesis for pre-clinical testing, as well as partnerships with contract development and manufacturing organizations for GMP-grade production. The small molecule pharma biocatalysis segment applies the company’s proprietary CodeEvolver directed evolution technology to develop optimized enzymes that enhance the efficiency, yield, and purity of small molecule therapeutic manufacturing for major pharmaceutical companies. Codexis also provides precision-tuned enzyme solutions for molecular biology and diagnostic applications. Founded in 2002, the company serves customers in the biopharmaceutical and chemical industries, with notable collaborations including the synthesis of sitagliptin with Merck and the production of an engineered enzyme for Pfizer’s COVID-19 antiviral. The company’s core technology, CodeEvolver, employs machine learning and high-throughput screening to design and optimize enzyme variants for specific industrial and therapeutic applications.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage codexis.com
Sector Healthcare IR page ir.codexis.com
Tags
enzyme engineering, sirna manufacturing, biocatalysis, directed evolution, rna therapeutics, pharmaceutical manufacturing, molecular biology, diagnostic applications, process development, contract manufacturing, CodeEvolver, ECO Synthesis, ECO Synthesis Innovation Lab, Januvia, Paxlovid
Press page ir.codexis.com/news-events/press-releases

Metrics

Valuation  
Market cap $ 124.535M
Market cap (USD) $ 124.535M
P/E -6.32
PEG —
P/BV 2.43
P/S 1.41
P/OCF -11.89
P/FCF -10.26
Dividend yield —
Turnover / mcap —
Returns  
ROE -74.9%
ROI -48.5%
ROIC -34.5%
Profit margin -62.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 80.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 9
Quality score -47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 70.387M 59.345M 70.143M 138.59M 104.754M 69.056M 68.458M 60.594M 50.024M 48.837M 41.804M 35.307M 31.922M 88.298M 123.865M 107.104M 82.908M
Net profit -43.974M -65.276M -76.24M -33.592M -21.279M -24.01M -11.935M -10.878M -22.996M -8.558M -7.581M -19.071M -41.303M -30.857M -16.55M -8.541M -20.289M
Free cash flow -23.847M -53.715M -57.056M 2.977M -28.095M -20.212M -16.29M -16.862M -9.748M -3.589M -1.632M 19K -24.173M -14.825M -11.226M -23.373M -19.483M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Share price 1.63 4.77 3.05 4.66 31.27 21.83 15.99 16.7 8.35 4.6 4.23 2.52 1.4 2.21 5.3 10.6 —
Price performance 12m -0.66 0.56 -0.35 -0.85 0.43 0.37 -0.04 1 0.82 0.09 0.68 0.8 -0.37 -0.58 -0.5 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 5.92M 11.8M 11.6M 9.03M 13.9M 25M 31.9M 10M 18.9M 10.7M
↳ YoY growth -19.2% +99.2% -2.1% -21.8% +53.9% +79.6% +27.9% -68.5% +88.2% -43.4%
↳ 5y CAGR -20.7% +9.4% +16.4% +18.5% +13.6% +33.3% +22.0% -2.8% +15.9% -5.1%
Borrowings, current (USD) — — — — — — — — — 0.00
Borrowings, non-current (USD) 0.00 302,000 — — — — — 0.00 28.9M 40.1M
Lease liabilities (USD) — — 61,000 26.1M 25M 47.7M 43.6M 22.4M 31M 33.1M
Cash and deposits (USD) 19.2M 31.2M 53M 90.5M 149M 117M 114M 65.1M 19.3M 50.8M
Intangible assets (USD) 0.00 — — — — — — — — —
Right-of-use assets (USD) — — 0.00 23.8M 21.4M 44.1M 39.3M 13.1M 28.7M 30.5M
Net debt (borrowings + leases - cash) (USD) -19.2M -30.9M — — — — — -49.1M 40.6M 22.4M
Cash flow detail
Operating cash flow (USD) -2.7M -8.76M -14.1M -12.6M -16.5M -14.3M 11.3M -52.6M -49.4M -19.4M
Purchases of property, plant and equipment (USD) -888,000 -985,000 -2.77M -3.73M -3.75M -13.8M -8.31M -4.42M -4.31M -4.47M
Change in receivables (cash effect) (USD) 1.41M -5.65M 960,000 2.52M — — — — — —
Change in inventories (cash effect) (USD) 167,000 -210,000 447,000 217,000 -593,000 -196,000 -869,000 -656,000 886,000 -19,000
Change in payables (cash effect) (USD) 942,000 -801,000 -524,000 -428,000 101,000 268,000 207,000 2.29M -2.57M -1.29M
Interest paid (cash effect) (USD) -14,000 -141,000 -84,000 -49,000 -52,000 -14,000 -34,000 -44,000 -2.57M -3.15M
Income taxes paid (cash effect) (USD) -5,000 -32,000 -5,000 -5,000 -312,000 -102,000 -100,000 -194,000 -17,000 0.00
Share-based compensation (USD) 5.67M 7.09M 7.89M 6.94M 7.73M 11.6M 14.5M 9.97M 13.1M 9.62M
Operating cash flow before change in receivables (USD) -4.11M -3.11M -15.1M -15.1M — — — — — —
Free cash flow (OCF - PPE - intangibles) (USD) -3.59M -9.75M -16.9M -16.3M -20.2M -28.1M 2.98M -57.1M -53.7M -23.8M
Income detail
Research and development expense (USD) 22.2M 29.7M 30M 33.9M 44.2M 55.9M 80.1M 58.9M 46.3M 52.3M
↳ 5y CAGR -18.3% -12.2% -1.1% +8.3% +16.4% +20.3% +22.0% +14.5% +6.4% +3.4%
Total comprehensive income (USD) -8.96M -23.5M -10.9M -11.9M — — -33.6M -76.2M -65.2M -44M
Comprehensive income to owners (USD) -8.96M -23.5M -10.9M -11.9M — — -33.6M -76.2M -65.2M -44M
Provision for credit losses (USD) 0.00 — — 0.00 40,000 342,000 4,000 -65,000 97,000 -113,000
Credit cost ratio (credit losses / average receivables) (%) 0.0% — — 0.0% 0.3% 1.8% 0.0% 0.3% 0.7% 0.8%
Reported Mar 15, 2018 Mar 15, 2018 May 8, 2019 Feb 28, 2022 Feb 28, 2022 Feb 28, 2022 Feb 27, 2025 Feb 27, 2025 Feb 27, 2025 Aug 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Redwood City, CA 94063 Bull 5 Bear 0 Results

+1 (650) 421-8100

codexis.com

Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update

Reports revenue of $19.3 million for the third quarter of 2026, company reiterates full-year revenue guidance

Shared new advances in RNA therapeutic manufacturing at TIDES Europe

Entered into a $60 million term loan facility with Trinity Capital; initial tranche used to refinance current debt

REDWOOD CITY, Calif., November 12, 2026 — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

“I am pleased with our outstanding progress in 2026, through both innovation and technical achievements, that has garnered attention from leading innovators in the siRNA field,” stated Alison Moore, PhD, President and Chief Executive Officer of Codexis.

Loan and Security Agreement On November 5, 2026 (the “Closing Date”), Codexis, Inc., a Delaware corporation (the “Company”) and its wholly owned subsidiary, Codexis Mayflower Holdings, LLC, a Delaware limited liability company (together with the Company, the “Borrowers”) entered into that certain Loan and Security Agreement (the “LSA”) with the lenders party thereto from time to time (the “Lenders”) and Trinity Capital Inc., as administrative agent and collateral agent for the Lenders (the “Agent”). The LSA provides for term loans in an aggregate principal amount of up to $60.0 million, available in three tranches: (a) a term loan of $42.5 million, which was funded on the Closing Date (the “Tranche A Loan”); (b) a term loan of $7.5 million, available at the Borrowers’ request through December 15, 2027, subject to customary conditions and to the ratio of the outstanding principal amount of the Loans (after giving pro forma effect to such loan) to the Company’s market capitalization, as defined in the LSA, not exceeding 20% (the “Tranche B Loan”); and (c) a term loan of $10.0 million, available through the end of the Interest Only Period (as defined below), subject to approval by the

October 29, 2026 9:00am EDT

REDWOOD CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the third quarter of 2026 on Thursday, November 12, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.

Participants may access the live webcast on the Codexis Investor Relations website , where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.

About Codexis

Codexis® is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis® manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com .

Prompts

Codexis, Inc. (ticker CDXS), listed in United States.

ETFs Holding Codexis, Inc.

ETF Weight in ETF Shares Market value As of
FEAC 0.05% 5,221 $ 11.799K Jun 30, 2026
RESM 0.01% 144 $ 325.44 Jun 30, 2026
FESM 0.01% 148,756 $ 336.189K Jun 30, 2026
AVSC 0.00% 3,960 $ 4,197.60 Nov 16, 2026